NEJM This Week — April 30, 2026

NEJM This Week delivers a comprehensive review of cutting-edge medical advances and critical health policy issues. The episode highlights zongertinib as a breakthrough first-line therapy for HER2-mutant non-small cell lung cancer, marking a major shift from chemotherapy and earning accelerated FDA approval. A cluster-randomized trial in Malawi and Uganda demonstrates that the APT-Sepsis program—focusing on hand hygiene, sepsis detection, and evidence-based practices—significantly reduces maternal infection-related deaths and complications in low-resource settings. In hemophilia A, the bispecific antibody MIM-8 shows superior bleeding prevention over standard treatments, offering new hope for patients with or without inhibitors. The Minidoc MTB test emerges as a highly accurate, user-friendly tool for diagnosing pulmonary tuberculosis using swab samples, potentially improving case detection in community clinics. The episode also explores complex clinical cases, including type 2 cryoglobulinemic vasculitis linked to lymphoma, and raises urgent concerns about GLP-1 drugs potentially exacerbating eating disorders, especially in vulnerable populations. Additional perspectives critique directed blood donation laws, question the safety assumptions behind generic drugs, and recount a haunting in-flight medical emergency that underscores the emotional toll of medical responsibility. Together, the episode underscores the power of targeted therapies, the importance of basic care quality, and the ethical and systemic challenges in modern medicine.